Angiochem to present new clinical data for ANG1005 in brain cancers at Society for Neuroscience meeting.

– ANG1005 and Angiochem’s EPiC platform to be Highlighted at Conference –

Montreal, Canada, and Chicago, IL, October 8, 2009 – AngioChem Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the treatment of brain cancers, as well as data showing how compounds from Angiochem’s Engineered Peptide Compounds (EPiC) platform are capable of crossing the blood-brain barrier will be highlighted at the Society for Neuroscience Annual Meeting in Chicago on October 17-21, 2009. In addition to poster presentations, ANG1005 and Angiochem’s EPiC platform will be the subject of a Society for Neurosciences-sponsored press conference, entitled “Crossing the Blood-Brain Barrier.” Angiochem will also be sponsoring a scientific symposia discussing new therapeutic approaches to crossing the bloodbrain barrier.

ANG1005 is a novel, next-generation taxane derivative, targeting the LRP pathway to cross the bloodbrain barrier and reach therapeutic concentrations in the brain. ANG1005 is in two separate Phase 1/2 clinical studies in patients with brain cancers and cancer metastases. The drug was created with
Angiochem’s Engineered Peptide Compound (EPiC) platform which harnesses the naturally-occurring LRP (low-density lipoprotein receptor-related protein) receptors on the surface of the blood-brain barrier.

The schedule is as follows:

• Society for Neuroscience Press Conference: Sunday, October 18, 2009, 11:00 a.m., “Crossing
  the Blood-Brain Barrier”, McCormick Place Conference Center, South 501D.
• Poster Presentation #185.1: Sunday, October 18, 8 a.m. – 12 p.m., “Development Of A New
  Engineered Peptide Compound (EPiC) Platform For The Transport Of Small And Large
  Therapeutics To The CNS”, Gabathuler, et.al., McCormick Place Conference Center, South Hall
  A.
• Poster Presentation #185.6: Sunday, October 18, 8 a.m. – 12 p.m., “Development Of A New
  Engineered Peptide Compound (EPiC) For The Treatment Of Malignant Glioma”, Drappatz, et.al.,
  McCormick Place Conference Center, South Hall A.
• Poster Presentation #185.2: Sunday, October 18, 8 a.m. – 12 p.m., “ANG1005: A promising new
  Engineered Peptide Compound (EPiC) for patients with advanced solid tumors and brain
  metastases”, Kurzrock, et. al., McCormick Place Conference Center, South Hall A.
• Scientific Breakfast Symposia: Monday, October 19, 6:30 - 8:30 a.m., “Crossing The Blood-Brain
  Barrier: New Therapeutic Approaches", Hyatt Regency McCormick Place, Room CC10CD –
  Level 1. This scientific symposia includes presentations and Q&A with leading scientific, medical
  and industry experts in the areas of CNS and oncology. The event will also be webcast and
  available on the Angiochem website at: http://phx.corporate-ir.net/phoenix.zhtml?p=iroleventDetails&
  c=232273&eventID=2482177.

About ANG1005 // ANG1005 is a novel, next-generation taxane derivative targeting the LRP pathway. ANG1005 was engineered with the EPiC platform which was designed to cross the blood-brain barrier (BBB). Studies have shown that ANG1005 gains entry into the brain compartment by targeting the low-density lipoprotein receptor-related protein (LRP) which is one of the most highly expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP, which is upregulated in various cancer cells including gliomas and metastatic brain cancers.

About AngioChem //Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier (BBB) to treat brain diseases. The company’s proprietary Engineered Peptide Compounds (EPiC) technology creates drugs that cross the BBB and reach therapeutic concentration in the brain, by harnessing naturally-occurring receptors on the surface of the BBB. Angiochem’s lead product candidate, ANG1005 is in two separate Phase 1/2 clinical studies in patients with brain cancers and cancer metastases. Additionally, Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the potential treatment of a wide range of CNS diseases, including neurodegenerative and metabolic diseases, brain cancer, psychiatric disorders and many others. Founded in 2006, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.